Sanofi of France has increased its stake in a joint venture with Usine 23, Sanofi Pharma Vietnam, from 50% to 70%. The move has been approved by the Vietnamese Health Ministry and the government committee for cooperation and investments.
In 1994, Sanofi's pharmaceutical sales in Vietnam, including both local and imported products, amounted to 40 million French francs ($8.1 million). Sanofi says that the deal will enable it to sustain the development of the joint-venture company, particularly in anticipation of additional industrial investments, and will result in an increase in sales of locally manufactured products.
The original agreement for the joint venture with Usine Nationale Pharmaceutique 23 was signed in November 1992. In January 1993, approval was granted by the Vietnamese government and the firm became operational in May 1993.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze